当一级市场对创新药的热情降温,医药产业链的权力结构却在悄悄重排。过去两年,中国Biotech融资规模明显收缩,不少管线被迫延缓甚至砍线,“烧钱换时间”的研发逻辑难以为继。药企开始更谨慎地计算每一笔临床支出,把原本自建团队完成的试验管理、数据统计、患者招募逐步外包出去,与其自己搭建一支庞大的临床队伍,不如把复杂流程交给更专业、更高效的服务商。于是,一个看似低调的赛道反而站上了聚光灯下:CRO。招股书...
Source Link当一级市场对创新药的热情降温,医药产业链的权力结构却在悄悄重排。过去两年,中国Biotech融资规模明显收缩,不少管线被迫延缓甚至砍线,“烧钱换时间”的研发逻辑难以为继。药企开始更谨慎地计算每一笔临床支出,把原本自建团队完成的试验管理、数据统计、患者招募逐步外包出去,与其自己搭建一支庞大的临床队伍,不如把复杂流程交给更专业、更高效的服务商。于是,一个看似低调的赛道反而站上了聚光灯下:CRO。招股书...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.